medigraphic.com

2016, Number S2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2016; 54 (S2)

High-intensity chemotherapy versus palliative chemotherapy in patients over 60 years with acute myeloid leukemia

Medrano-Contreras J, Talavera-Piña JO, Guerrero-Rivera S, Gutiérrez-Espíndola GR, Gómez-Cortés C, Pérez-Rocha JF, Terreros-Muñoz E, Meillón-García LA

Language: Spanish
References: 32
Page: 148-155
PDF size: 854.31 Kb.


ABSTRACT

Background: The use of high-intensity chemotherapy (HIC) for acute myeloid leukemia (AML) in the elderly is controversial. In the present study, it was assessed complete remission and overall survival of AML patients over 60 years treated with HIC or palliative chemotherapy.
Methods: Patients with ECOG ≤ 2 and adequate organic function received HIC with a base of cytarabine for five or seven days, and an anthracycline for three days. If patients achieved complete remission of leukemia, they received one or two cycles of consolidation with cytarabine. Palliative treatment consisted of supported measures and/or oral or intravenous low-dose chemotherapy.
Results: Seven patients treated with HIC achieved complete remission versus only one in the palliative group. Only one patient died during HIC treatment. Median survival for HIC-treated patients was 13.25 months, and only 3.35 months for patients treated with palliative therapy (p ‹ 0.05).
Conclusion: AML patients of 60 years or older, with good performance status (ECOG ≤ 2) and adequate organ function, may benefit from HIC treatment, with better survival, compared with palliative therapy.


REFERENCES

  1. Brinker H. Population-based age and sex specific incidence rates in the four main types of leukemia. Scand J Hematol. 1982;29:241-9.

  2. Sekeres MA, Stone RM. The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol. 2002;14:24-30.

  3. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, et al. A randomized study of a high dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710-7.

  4. Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standart-dose with daunorrubicin and 6-thioguanine. A randomized trial by the German AML cooperative group. Blood. 1999;93:4116-24.

  5. Rowe JM. Treatment of acute myelogenous leukemia in older adults. Leukemia. 2000;14:480-7. Disponible en http://www.nature.com/leu/journal/v14/n3/ full/2401539a.html

  6. Büchner T, Berder WE, Haferlach T, Schinittger S, Miller- Tidow C, Braess J, et al. Age related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol. 2009;27:61-9.

  7. Frohling S, Schlenk RF, Kayser S. Morhardt M, Banner A, Dohner H. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108(10):3280-8.

  8. Leith CP, Kopecky KJ, Godwin J, McConell T, Slovac ML, Chen IM. Acute leukemia myeloid in the elderly: Assessment of the multidrug resistance (MDR1) and cytogenetic distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A southwest Oncology Group Study. Blood. 1997;89:3323-9.

  9. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17:3569-76.

  10. Mauritzson N, Johansson B, Albin M, Rylander I, Billstrom R, Ahlgren T. Survival time in a population-based series of adult acute myeloid leukemia: the prognostic impact of Karyotype during the time period 1976-1993. Leukemia. 2000;14:1039-43.

  11. Hestey EH. Prognostic factors in acute myelogenous leukemia. Leukemia. 2001;15:670-2.

  12. Anderson JE, Kopecky KJ, Willman CL, Head D, O’Donell MR, Luthardt FW, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood. 2002;100:3869-76.

  13. Lowenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GE, Vellenga E, et al. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patient aged 61 years and older with acute myeloid leukemia: a final report of AML-11; a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood. 1997;90:2952-61.

  14. Lowenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy. The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.. J Clin Oncol. 1998;16:872-81.

  15. Yoshida S, Kuriyama K, Miyazaki Y, Taguchi J, Fukushima T, Honda M, et al. De novo acute myeloid leukemia in the elderly; a consistent fraction of long-term survivors by standard-dose chemotherapy. Leuk Res. 2001 Jan;25(1):33-38.

  16. López A, De la Rubia J, Martín G, Martínez J, Cervera J, Jarque I. Recent improvements in outcome for elderly patient with de novo acute myeloblastic leukemia. Leuk Res. 2001;25:685-92.

  17. Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prisé PY, Tertian G, et al. Low-dose cytarabine vs. intensive chemotherapy in the treatment of acute nonlimphocytic leukemia in the elderly. J Clin Oncol. 1990;8(2):272-9.

  18. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, et al. Granulocyte-macrophage colony- stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995 Jun 22;332(25):1671-7.

  19. Pulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Crugnola M, et al. Survival of elderly patients with acute myeloid leukemia. Haematologica. 2004 Mar;89(3):296-302.

  20. Rodríguez JN, Fernández-Jurado A, Martino ML, Dieguez JC, Moreno MV, Quesada JA, et al. Leucemia mieloide aguda en mayores de 70 años. Experiencia utilizando tratamiento con ara-C a bajas dosis. Sangre (Barc). 1998;43(1):35-39.

  21. Doubek M, Palasek I, Brychtova Y, Buchtova I, Mayer J. Acute myeloid leukemia treatment in patient over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy. Neoplasma. 2005;52(5):411-4.

  22. Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, et al. Age and acute myeloid leukemia: real data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009 Apr 30;113(18):4179-87. doi: 10.1182/ blood-2008-07-172007.

  23. Röllig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhäuser M, et al. A novel prognostic model in erderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML 96 trial. Blood. 2010 Aug 12;116(6):971-8. doi: 10.1182/ blood-2010-01-267302.

  24. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukemia. Br J Haematol. 1976 Aug;33(4):451-8.

  25. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute leukemia. J Clin Oncol. 1990;8:813-19.

  26. Buitrón-Santiago N, Arteaga-Ortíz L, Rosas-López A, Aguayo A, López-Karpovitch X, Crespo-Solís E. Leucemia mieloide aguda en adultos: experiencia del Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán de 2003 a 2008. Rev Inv Clin. 2010;62:100-8.

  27. Lobato-Mendizábal E, Ruíz-Argüelles GJ, Labardini- Méndez J, Gómez-Almaguer D, Ganci-Cerrud G, Lozano- de la Vega A. Comparación de 2 protocolos de quimioterapia en adultos con leucemia mieloblastica aguda. Resultados del Instituto Nacional de la Nutrición Salvador Zubirán grupo cooperativo. Rev Inv Clin. 1992;44:63-9.

  28. Mohamedali H, Breunis H, Timilshina N, Brandwein JM, Gupta V, Minden MD, et al. Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia. Leuk Res. 2012:1241-8.

  29. DeLima M, Ghaddar H, Pierce S, Estey E. Treatment of newly-diagnosed acute myelogenous in patient aged 80 years and above. Br J Hematol. 1996;93:89-95.

  30. Lowenberg B. Managing therapy in older patient with acute myeloid leukaemia. Sem Hematol. 2001;38:10-16.

  31. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison Ch, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood. 2001; 98:1312-20.

  32. Ferrara F, Pinto A. Acute Myeloid Leukemia in the elderly: current therapeutic results and perspectives for clinical research. Rev Recent Clin Trials. 2007;2:33-41.




2020     |     www.medigraphic.com